Judge Upholds Pfizer’s Patent for Norvasc

A federal judge upheld the validity of Pfizer Inc.’s U.S. patent covering the active ingredient in Norvasc, the world’s top-selling blood-pressure medication.

The ruling in Durham, N.C., blocks Dutch generic drug maker Synthon from selling a cheaper copy of Norvasc until at least September 2007, when the patent expires.